Skip to main content

Table 3 Severity of symptoms at baseline, during 16 weeks’ treatment and after one month’s follow-up)

From: A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome

Severity of IBS-D

Probiotic (Bio-Kult®) (n = 181)

Placebo (n = 179)

P-value

Baseline

 Moderate

39 (21.5)

52 (29.1)

0.101

 Severe

142 (78.5)

127 (70.9)

Month 1

 Symptoms free period

2 (1.1)

2 (1.1)

0.086

 Mild

78 (43.1)

58 (32.4)

 Moderate

91 (50.3)

99 (55.3)

 Severe

10 (5.5)

20 (11.2)

Month 2

 Symptoms free period

16 (8.8)

18 (10.1)

< 0.001

 Mild

112 (61.9)

61 (34.1)

 Moderate

42 (23.2)

82 (45.8)

 Severe

11 (6.1)

18 (10.1)

Month 3

 Symptoms free period

54 (29.8)

20 (11.2)

< 0.001

 Mild

98 (54.1)

62 (34.6)

 Moderate

23 (12.7)

57 (31.8)

 Severe

6 (3.3)

40 (22.3)

Month 4

 Symptoms free period

56 (30.4)

22 (11.2)

< 0.001

 Mild

99 (54.7)

68 (38.0)

 Moderate

21 (11.6)

66 (36.9)

 Severe

6 (3.3)

23 (12.8)

Follow-up: Month 5

 Symptoms free period

61 (33.7)

23 (12.8)

< 0.001

 Mild

95 (52.5)

70 (39.1)

 Moderate

21 (11.6)

65 (36.3)

 Severe

4 (2.2)

21 (11.7)

  1. The unpaired Chi-square test was used to determine the level of statistical significance